160 related articles for article (PubMed ID: 23842135)
1. Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.
Prach LM; Pascopella L; Barry PM; Flood J; Porco TC; Hopewell PC; Metcalfe JZ
AIDS; 2013 Oct; 27(16):2615-22. PubMed ID: 23842135
[TBL] [Abstract][Full Text] [Related]
2. Rifampin-resistant Tuberculosis in the United States, 1998-2014.
Sharling L; Marks SM; Goodman M; Chorba T; Mase S
Clin Infect Dis; 2020 Apr; 70(8):1596-1605. PubMed ID: 31233131
[TBL] [Abstract][Full Text] [Related]
3. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA
Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283
[TBL] [Abstract][Full Text] [Related]
7. Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
Sanchez-Padilla E; Ardizzoni E; Sauvageot D; Ahoua L; Martin A; Varaine F; Adatu-Engwau F; Akeche G; Salaniponi F; Bonnet M
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1036-42. PubMed ID: 23827027
[TBL] [Abstract][Full Text] [Related]
8. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
[TBL] [Abstract][Full Text] [Related]
9. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.
Mukinda FK; Theron D; van der Spuy GD; Jacobson KR; Roscher M; Streicher EM; Musekiwa A; Coetzee GJ; Victor TC; Marais BJ; Nachega JB; Warren RM; Schaaf HS
Int J Tuberc Lung Dis; 2012 Feb; 16(2):196-202. PubMed ID: 22236920
[TBL] [Abstract][Full Text] [Related]
10. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.
Fox L; Kramer MR; Haim I; Priess R; Metvachuk A; Shitrit D
Eur J Clin Microbiol Infect Dis; 2011 Jul; 30(7):863-7. PubMed ID: 21431989
[TBL] [Abstract][Full Text] [Related]
11. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil.
Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR
Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771
[TBL] [Abstract][Full Text] [Related]
12. Drug-resistant TB prevalence study in 5 health institutions in Haiti.
Hoffmann J; Chedid C; Ocheretina O; Masetti C; Joseph P; Mabou MM; Mathon JE; Francois EM; Gebelin J; Babin FX; Raskine L; Pape JW
PLoS One; 2021; 16(3):e0248707. PubMed ID: 33735224
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study.
He XC; Zhang XX; Zhao JN; Liu Y; Yu CB; Yang GR; Li HC
Medicine (Baltimore); 2016 Apr; 95(15):e3336. PubMed ID: 27082586
[TBL] [Abstract][Full Text] [Related]
14. High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients.
Velayati AA; Farnia P; Mozafari M; Sheikholeslami MF; Karahrudi MA; Tabarsi P; Hoffner S
Am J Trop Med Hyg; 2014 Jan; 90(1):99-105. PubMed ID: 24189362
[TBL] [Abstract][Full Text] [Related]
15. Rifampin-resistant, isoniazid-susceptible TB in HIV patients.
Pugliese G
Infect Control Hosp Epidemiol; 1995 Nov; 16(11):622. PubMed ID: 8601679
[No Abstract] [Full Text] [Related]
16. Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years.
Baghaei P; Tabarsi P; Moniri A; Marjani M; Farnia P; Jabbehdari S; Velayati AA
J Glob Antimicrob Resist; 2017 Dec; 11():116-119. PubMed ID: 28739225
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance among persons with tuberculosis in California, 1994-2003.
Granich RM; Oh P; Lewis B; Porco TC; Flood J
JAMA; 2005 Jun; 293(22):2732-9. PubMed ID: 15941802
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
Liu Z; Shilkret KL; Finelli L
Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705
[TBL] [Abstract][Full Text] [Related]
19. Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy.
Sungkanuparph S; Eampokalap B; Chottanapund S; Bed ST; Manosuthi W
J Med Assoc Thai; 2007 May; 90(5):884-8. PubMed ID: 17596041
[TBL] [Abstract][Full Text] [Related]
20. Nationwide survey of drug-resistant tuberculosis in the United States.
Bloch AB; Cauthen GM; Onorato IM; Dansbury KG; Kelly GD; Driver CR; Snider DE
JAMA; 1994 Mar; 271(9):665-71. PubMed ID: 8080502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
